News and updates from IPOX®, including media mentions, interviews, research and press releases.
IPOX® CEO Josef Schuster spoke with Bloomberg about the expected rebound in US energy IPOs, driven by companies like Venture Global. Schuster noted rising commodity prices and recent IPO successes create a favorable environment, adding that the market is "ready for a slew of good energy IPOs."
IPOX® CEO Josef Schuster sat down with Chuck Jaffe on the Money Life with Chuck Jaffe podcast to discuss the state of the IPO market, its strong performance amid market highs, and the factors driving its momentum. Schuster highlighted the role of low interest rates, robust earnings, and the rise of sectors like AI and industrials in fueling IPO growth.
Josef Schuster, founder and CEO of IPOX® Schuster LLC, was recently featured in Reuters, offering his perspective on the upcoming IPO of ServiceTitan, which aims for a valuation of up to $5.16 billion.
IPOX® CEO Josef Schuster shared insights with Bloomberg on the renewed optimism in Canada’s IPO market, highlighted by Groupe Dynamite Inc.’s C$300 million debut. Schuster emphasized the IPOX® Canada Opportunities Index's adaptability, which has delivered a strong 36% return this year, outperforming the S&P/TSX Composite Index. The index reflects growing investor confidence and emerging opportunities as Canada’s equity markets show signs of recovery.
IPOX® CEO Josef Schuster, portfolio manager and subadvisor to the Rakuten Global IPO Stock Fund, was featured in Japan’s Nikkei Newspaper (日本経済新聞), talking about Reddit’s impressive post-IPO growth, underscoring IPOX®'s focus on identifying high-potential companies in the evolving global IPO landscape.
IPOX® Research Analyst Dr. Lukas Muehlbauer commented on Septerna's upsized U.S. IPO as the Goldman Sachs-backed drug developer targets a valuation of $743.1 million. Septerna, originally planning to offer 10.9 million shares within a $15-$17 range, has now increased its offering to 15.3 million shares, pricing them at $18 each, to raise approximately $275 million. This move reflects positive investor sentiment for biotech IPOs, which have seen strong performances in the U.S. market this fall.
In a recent Reuters article, IPOX® CEO Dr. Josef Schuster highlighted the strategic timing behind Ingram Micro's return to the U.S. stock market, as the global technology distributor seeks a valuation of up to $5.42 billion. Schuster emphasized that private equity firms, like Ingram's backer Platinum Equity, are capitalizing on favorable market conditions, strong demand, and the opportunity to monetize their investments.
In a recent Reuters article, IPOX® Research Analyst Dr. Lukas Muehlbauer discussed the strong debut of Upstream Bio (UPB.O) in the IPO market. The Waltham, Massachusetts-based drug developer saw its stock rise 26.5% above the IPO price, giving it a market value of $1.05 billion.
In a recent Reuters article, IPOX® research analyst Lukas Muehlbauer highlighted strong institutional and retail demand for Bicara Therapeutics' IPO, which raised $315 million after upsizing twice. Bicara’s shares surged 46% in its debut, driven by confidence in its lead anti-cancer drug and notable backing from TPG and Biocon.